MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
54.39%
Quick Ratio
54.39%
Cash Ratio
46.73%
Debt to Asset Ratio
359.92%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Operating lease right-of-use ass...
    • Other assets
    • Prepaid expenses and other curre...
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Warrant liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
3,431
6,243
3,006
5,927
Prepaid expenses and other current assets
562
382
392
1,485
Total current assets
3,993
6,625
3,398
7,412
Property and equipment, net
123
142
162
181
Operating lease right-of-use asset
931
992
1,052
1,112
Other assets
863
871
948
29
Total assets
5,910
8,630
5,560
8,734
Accounts payable
2,697
1,481
942
2,525
Accrued clinical trials expenses
933
1,173
1,426
1,524
Accrued compensation
1,897
1,832
2,872
1,547
Other accrued expenses
1,815
2,183
1,657
2,632
Total current liabilities
7,342
6,669
6,897
8,228
Convertible notes at fair value, including related party amount of 1,755 and 34,600 at june 30, 2026 and december 31, 2025, respectively
1,755
1,542
34,600
17,051
Operating lease liability
757
825
893
957
Derivative liability
-
-
14,879
-
Warrant liabilities
11,367
16,308
3,276
2,338
Contingent consideration liability
27
38
42
32
Other liabilities
23
-
-
-
Total liabilities
21,271
25,382
60,587
28,606
Class a common stock, 0.0001 par value 1,040,000,000 and 500,000,000 shares authorized at june 30, 2026 and december 31, 2025, and 26,307,211 and 12,105,902 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively
10
10
9
9
Additional paid-in capital
468,396
465,850
415,783
413,801
Accumulated deficit
-483,767
-482,612
-470,819
-433,682
Total stockholders' deficit
-15,361
-16,752
-55,027
-19,872
Total liabilities and stockholders' deficit
5,910
8,630
5,560
8,734
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$3,431K (-59.34%↓ Y/Y)Prepaid expenses andother current assets$562K (-69.17%↓ Y/Y)Total current assets$3,993K (-61.09%↓ Y/Y)Operating leaseright-of-use asset$931K (-20.50%↓ Y/Y)Other assets$863K (2875.86%↑ Y/Y)Property and equipment,net$123K (-38.50%↓ Y/Y)Total assets$5,910K (-49.32%↓ Y/Y)Accumulated deficit-$483,767K (-12.73%↓ Y/Y)Total liabilities andstockholders' deficit$5,910K (-49.32%↓ Y/Y)Total stockholders'deficit-$15,361K (3.10%↑ Y/Y)Additional paid-in capital$468,396K (13.34%↑ Y/Y)Class a common stock,0.0001 par value...$10K (11.11%↑ Y/Y)Total liabilities$21,271K (-22.69%↓ Y/Y)Warrant liabilities$11,367K (435.67%↑ Y/Y)Total currentliabilities$7,342K (-19.57%↓ Y/Y)Convertible notes at fairvalue, including...$1,755K (-88.43%↓ Y/Y)Operating lease liability$757K (-25.78%↓ Y/Y)Contingent considerationliability$27K (-60.87%↓ Y/Y)Other liabilities$23K Accounts payable$2,697K (-30.97%↓ Y/Y)Accrued compensation$1,897K (247.44%↑ Y/Y)Other accruedexpenses$1,815K (-39.52%↓ Y/Y)Accrued clinical trialsexpenses$933K (-44.30%↓ Y/Y)

AEON Biopharma, Inc. (AEON)

AEON Biopharma, Inc. (AEON)